GLP-1 Price Guide Compare prices
Next-Gen GLP-1 · June 1, 2026

What Is Retatrutide? The Next-Generation GLP-1 Explained

Retatrutide (LY3437943) is Eli Lilly's investigational triple-agonist peptide drug. It binds three receptors and produces greater weight loss than current GLP-1 drugs in Phase 2 trials.

Retatrutide & Next-GenJune 1, 2026Editorial
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Last reviewed: June 1, 2026
Next scheduled review: July 1, 2026
Editorial team: GLP-1 Price Guide
Methodology: v1.0 pricing framework

See our full retatrutide guide. Retatrutide is investigational and not commercially available. It is currently legally available only to participants in Eli Lilly's Phase 3 TRIUMPH clinical trials.

The triple-agonist mechanism: GLP-1 + GIP + glucagon receptor agonism. Phase 2 trials showed ~24% mean weight loss at 48 weeks at the highest dose — exceeding tirzepatide's ~22% in SURMOUNT trials.

Frequently asked questions

Can I buy retatrutide online?
No. Retatrutide is investigational and not commercially available. Vendors selling 'retatrutide' online are selling research-peptide analogs or unauthorized products.

Sources reviewed

  • Provider pricing pages (live as of June 1, 2026)
  • Provider terms, refund, and support pages
  • Third-party pricing comparisons and analyst reports
  • FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Drug Shortages database
  • DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
  • NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
  • Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
  • State Board of Pharmacy licensure lookups (varies by state)
  • Federation of State Medical Boards — FSMB DocInfo physician verification
  • LegitScript healthcare merchant directory (where applicable)
Important medical and regulatory disclosure Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.